A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Chronic Pain, Nociceptive Pain, Pain
In brief
A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an open-label, 2-period crossover, food effect cohort.
Key facts
- Study ID
- NCT04154501
- Run by
- Centrexion Therapeutics
- People needed
- 68
- Starts
- 2018-12-04
- Expected to finish
- 2019-08-26
- Last updated by the study team
- 2019-11-06
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Altasciences Clinical Research — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.